This is Prime Therapeutics’ latest research into GLP-1s and the long term impact of taking the medication. In October of last ...

Williams is entrepreneur-in-residence and is will help mentor and support women leading ventures supported by the program. Reckitt announced Reckitt Catalyst at the Cannes Lions International Festival ...

Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, discusses how early data from ABBV-706 shows up to 50% ...

Final results from the Phase IV PEARL trial show that 66% of patients treated with Ajovy for episodic migraine and more than half of those treated for chronic migraine who responded during the first ...

Under terms of the deal, Kymera will lead early research on novel oral CDK2 degraders for solid tumors, with Gilead assuming ...